$2.91
-0.33 (-10.06%)
Open$3.23
Previous Close$3.23
Day High$3.37
Day Low$2.78
52W High$10.99
52W Low$2.55
Volume—
Avg Volume1.31M
Market Cap238.47M
P/E Ratio—
EPS$-1.16
SectorBiotechnology
Analyst Ratings
Strong Buy
16 analysts
Price Target
+1,499.7% upside
Current
$2.91
$2.91
Target
$46.47
$46.47
$27.16
$46.47 avg
$57.70
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 110.56M | 98.68M | 97.87M |
| Net Income | 17.37M | 14.67M | 15.60M |
| Profit Margin | 15.7% | 14.9% | 15.9% |
| EBITDA | 19.93M | 19.03M | 18.02M |
| Free Cash Flow | 11.85M | 8.63M | 11.57M |
| Rev Growth | +16.0% | -2.8% | +7.5% |
| Debt/Equity | 0.49 | 0.46 | 0.54 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $291.31 | +1.07% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $460.42 | +0.03% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $166.89 | -0.41% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $547.09 | +0.85% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $904.35 | +0.16% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $155.94 | -0.46% | 7.7 | 20.98B |